|
|
|
| Effect of Rosuvastatin on blood lipid,inflammatory factors and carotid atherosclerotic plaque in patients with cerebral infarction |
| TANG Pei-lan WU Da-hua▲ XIE Le FAN Jian-hu |
| Department of Encephalopathy,the Affiliated Hospital of Hu′nan Institute of Traditional Chinese Medicine,Hu′nan Province,Changsha 410006,China |
|
|
|
|
Abstract Objective To investigate the effect of Rosuvastatin on blood lipid,inflammatory factors and carotid atherosclerotic plaque in patients with cerebral infarction.Methods A total of 80 patients with acute cerebral infarction and carotid atherosclerotic plaque treated in our hospital from January 2017 to April 2018 were selected as the study objects,and divided into the observation group and control group by the random number table method,with 40 cases in each group.The observation group used Rosuvastatin,and the control group used Atorvastatin.The changes of blood lipid indexes and inflammatory factors between the two groups were compared,and the incidence of carotid plaque hemorrhage and plaque fibrous cap rupture were compared.Results The levels of lipid-related total cholesterol,triglyceride and low density lipoprotein the observation group were lower than those in the control group,and the level of high density lipoprotein was higher than that in the control group,the differences were statistically significant (P＜0.05).Three months after treatment,the levels of inflammatory factors such as hypersensitive C-reactiveprotein (hs-CRP) and interleukin-6 (IL-6) in the observation group were lower than those in the control group,and the differences were statistically significant (P＜0.05).One-year follow-up,the incidence rates of internal hemorrhage of carotid plaque and rupture of plaque fibrous cap in the observation group were lower than those in the control group,and the differences were statistically significant (P＜0.05).Conclusion For acute cerebral infarction,Rosuvastatin is an ideal lipidregulating agent,which can reduce the level of inflammatory response and reduce the incidence of plaque lesions.
|
|
|
|
|
|
| [1] |
卢竞，吴东岳，吴魏霞.瑞舒伐他汀辅助治疗对急性脑梗死合并糖尿病患者血脂、炎症因子水平的影响观察[J].北方药学，2019，16（5）：57-58.
|
| [2] |
雷东华，秦爱萍，王静敏.丹红注射液联合瑞舒伐他汀对2 型糖尿病合并脑梗死患者血管舒张功能的影响[J].中医药临床杂志，2019，31（2）：307-309.
|
| [3] |
张敏，于莉，郑美玲，等.丁苯酞注射液联合瑞舒伐他汀钙片治疗急性进展性脑梗死的临床研究[J].中国临床药理学杂志，2019，35（3）：203-205.
|
| [4] |
钟丽珍，赵华，王璐，等.蛭蛇通络胶囊联合瑞舒伐他汀治疗脑梗死伴颈动脉粥样硬化斑块的临床研究[J].中国煤炭工业医学杂志，2019，22（1）：91-94.
|
| [5] |
叶晓歌，尤良军.盐酸小檗碱联合瑞舒伐他汀钙治疗33例急性缺血性脑梗死患者的疗效分析[J].黑龙江医药科学，2019，42（1）：148-149.
|
| [6] |
邰炜彦，王璟，吴璇，等.心可舒片联合瑞舒伐他汀治疗不稳定型心绞痛的临床疗效观察[J].中西医结合心脑血管病杂志，2019，17（1）：118-120.
|
| [7] |
Liu Y，Yang H，Jia G，et al.The synergistic neuroprotective effects of combined rosuvastatin and resveratrol pretreatment against cerebral ischemia/reperfusion injury[J].J Stroke Cerebrovasc Dis，2018，27（6）：1697-1704.
|
| [8] |
姚丽娜，李美杰，王艳珍，等.瑞舒伐他汀和阿托伐他汀对急性脑梗死病人血脂与颈动脉粥样硬化斑块的影响[J].中西医结合心脑血管病杂志，2018，16（24）：3714-3717.
|
| [9] |
Qiu Y，Wu Y，Meng M，et al.Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats[J].Biomed Pharmacother，2017，87（4）：503-508.
|
| [10] |
关赟.阿替普酶联合瑞舒伐他汀对急性脑梗死患者血脂及神经功能的影响[J].医学理论与实践，2018，31（22）：3364-3366.
|
| [11] |
文洪波，杨军，孙树乾，等.阿托伐他汀及瑞舒伐他汀治疗脑梗死患者的临床效果分析[J].慢性病学杂志，2018，19（11）：1484-1488.
|
| [12] |
冯念，卢沈华，潘少华.不同剂量瑞舒伐他汀对肥胖急性脑梗死患者溶栓后血清内脏脂肪特异性丝氨酸蛋白酶抑制剂和网膜素-1 水平及神经功能恢复的影响[J].微循环学杂志，2018，28（4）：47-51.
|
| [13] |
陈娟燕，宋水江，徐冬娟，等.法舒地尔联合瑞舒伐他汀治疗血管性痴呆对认知功能、C-反应蛋白及氧化应激的影响[J].中国临床药理学与治疗学，2018，23（10）：1153-1158.
|
| [14] |
王娟，郭岩.瑞舒伐他汀和阿托伐他汀治疗急性脑梗死疗效及对患者神经功能影响比较研究[J].陕西医学杂志，2018，47（10）：1331-1333.
|
| [15] |
钟彩琴，吕俊杰.阿托伐他汀或瑞舒伐他汀分别联合氯吡格雷在脑梗死二级预防中的效果差异[J].中国现代药物应用，2018，12（17）：82-83.
|
| [16] |
黄永禄.瑞舒伐他汀在不同时间窗治疗脑梗死临床疗效及对患者神经功能缺损和炎性因子的影响[J].脑与神经疾病杂志，2018，26（9）：547-551.
|
| [17] |
胡美铃，李伟英，王志敏.丁苯酞联合瑞舒伐他汀治疗动脉粥样硬化型脑梗死的疗效观察[J].浙江实用医学，2018，23（4）：242-244，263.
|
| [18] |
果晓明.阿司匹林与瑞舒伐他汀联合治疗老年急性脑梗死患者的有效性及安全性[J].中国药物经济学，2018，13（8）：96-98.
|
|
|
|
